Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. More Details
No risks detected for CSII from our risk checks.
Excellent balance sheet with reasonable growth potential.
Share Price & News
How has Cardiovascular Systems's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: CSII is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: CSII's weekly volatility (5%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: CSII exceeded the US Medical Equipment industry which returned 28.6% over the past year.
Return vs Market: CSII underperformed the US Market which returned 36.9% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Cardiovascular Systems's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDid You Miss Cardiovascular Systems' (NASDAQ:CSII) Impressive 100% Share Price Gain?
4 weeks ago | Simply Wall StAre Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 28%?
1 month ago | Simply Wall StIs Now The Time To Look At Buying Cardiovascular Systems, Inc. (NASDAQ:CSII)?
Is Cardiovascular Systems undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: CSII ($39.24) is trading below our estimate of fair value ($68.89)
Significantly Below Fair Value: CSII is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: CSII is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: CSII is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CSII's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CSII is overvalued based on its PB Ratio (5.8x) compared to the US Medical Equipment industry average (4.6x).
How is Cardiovascular Systems forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CSII is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: CSII is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CSII's is expected to become profitable in the next 3 years.
Revenue vs Market: CSII's revenue (12.2% per year) is forecast to grow faster than the US market (9.3% per year).
High Growth Revenue: CSII's revenue (12.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CSII's Return on Equity is forecast to be high in 3 years time
How has Cardiovascular Systems performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: CSII is currently unprofitable.
Growing Profit Margin: CSII is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: CSII is unprofitable, but has reduced losses over the past 5 years at a rate of 27.8% per year.
Accelerating Growth: Unable to compare CSII's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CSII is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (15.5%).
Return on Equity
High ROE: CSII has a negative Return on Equity (-8.62%), as it is currently unprofitable.
How is Cardiovascular Systems's financial position?
Financial Position Analysis
Short Term Liabilities: CSII's short term assets ($285.3M) exceed its short term liabilities ($50.4M).
Long Term Liabilities: CSII's short term assets ($285.3M) exceed its long term liabilities ($26.0M).
Debt to Equity History and Analysis
Debt Level: CSII is debt free.
Reducing Debt: CSII had no debt 5 years ago.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CSII has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CSII has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Cardiovascular Systems's current dividend yield, its reliability and sustainability?
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CSII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CSII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CSII's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CSII's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CSII's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Ward (61 yo)
Mr. Scott Raymond Ward, MS, B.Sc., has been the Chief Executive Officer and President of Cardiovascular Systems Inc. since August 15, 2016 and served as an Interim Chief Executive Officer and Interim Presi...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD4.72M) is about average for companies of similar size in the US market ($USD3.72M).
Compensation vs Earnings: Scott's compensation has increased whilst the company is unprofitable.
Experienced Management: CSII's management team is considered experienced (4 years average tenure).
Experienced Board: CSII's board of directors are considered experienced (4.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: CSII insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Cardiovascular Systems, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Cardiovascular Systems, Inc.
- Ticker: CSII
- Exchange: NasdaqGS
- Founded: 1989
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$1.576b
- Shares outstanding: 40.16m
- Website: https://www.csi360.com
Number of Employees
- Cardiovascular Systems, Inc.
- 1225 Old Highway 8 Northwest
- Saint Paul
- United States
Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral arte...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/07/24 01:50|
|End of Day Share Price||2021/07/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.